Managing Atrial Fibrillation - 23/04/15

, Tyler W. Barrett, MD MSCI bPlan
| Editor's Note: The Expert Clinical Management series consists of shorter, practical review articles focused on the optimal approach to a specific sign, symptom, disease, procedure, technology, or other emergency department challenge. These articles—typically solicited from recognized experts in the subject area—will summarize the best available evidence relating to the topic while including practical recommendations where the evidence is incomplete or conflicting. |
|
| Supervising editor: Judd E. Hollander, MD |
|
| Funding and support: By Annals policy, all authors are required to disclose any and all commercial, financial, and other relationships in any way related to the subject of this article as per ICMJE conflict of interest guidelines (see www.icmje.org/). The authors have stated that no such relationships exist and provided the following details: Dr. Atzema is supported by a New Investigator Award from the Heart and Stroke Foundation. Dr. Barrett is supported by National Institutes of Health grant K23 HL102069 from the National Heart, Lung, and Blood Institute. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Dr. Barrett serves as a scientific consultant for Red Bull GmbH and Boehringer Ingelheim Pharmaceuticals, Inc. on non–atrial fibrillation diseases. |
|
| A podcast for this article is available at www.annemergmed.com. |
Vol 65 - N° 5
P. 532-539 - mai 2015 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
